Described are compounds of Formula I and Formula II and their pharmaceutically
acceptable salts. The compounds of Formulas I and II are antagonists of NMDA receptor
channel complexes useful for treating cerebral vascular disorders such as, for
example, cerebral ischemia, cardiac arrest, stroke, and Parkinson's disease.
##STR1##